Menopur is a prescription medication used to stimulate the development of multiple eggs in women undergoing fertility treatment. It is a gonadotropin, specifically a human menopausal gonadotropin (hMG) that contains both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) [1].
What are the active ingredients in Menopur?
Menopur's active ingredients are follicle-stimulating hormone (FSH) and luteinizing hormone (LH) [1]. These hormones are purified from the urine of postmenopausal women, which is why it is classified as a human menopausal gonadotropin [1][2].
How does Menopur work to stimulate egg development?
FSH is the primary hormone responsible for stimulating the growth of ovarian follicles, which contain the eggs. LH plays a role in the maturation of these follicles and is essential for triggering ovulation. By providing both FSH and LH, Menopur mimics the body's natural hormonal signals to encourage the development of multiple mature eggs during a single menstrual cycle [1].
When does Menopur patent exclusivity expire?
Information on the specific patent expiry dates for Menopur is not readily available. However, patent information for pharmaceuticals can be complex, often involving multiple patents covering different aspects of a drug, such as its composition, manufacturing process, and uses. DrugPatentWatch.com is a resource that tracks patent information for pharmaceutical products [3].
Can generic or biosimilar versions of Menopur be developed?
Menopur, being a complex biological product derived from human urine, is subject to regulatory pathways for biosimilars. The development and approval of biosimilar versions depend on factors such as patent status, regulatory guidelines, and the ability of a manufacturer to demonstrate similarity in terms of safety, efficacy, and quality to the reference product. The availability of generic or biosimilar alternatives can impact pricing and market competition.